↓ Skip to main content

Michigan Publishing

TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer…

Overview of attention for article published in BMC Cancer, October 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter
16 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
268 Mendeley
Title
TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial
Published in
BMC Cancer, October 2017
DOI 10.1186/s12885-017-3652-3
Pubmed ID
Authors

D. Wittmann, A. Mehta, L. Northouse, R. Dunn, T. Braun, A. Duby, L. An, L. Arab, R. Bangs, S. Bober, J. Brandon, M. Coward, M. Dunn, M. Galbraith, M. Garcia, J. Giblin, M. Glode, B. Koontz, A. Lowe, S. Mitchell, J. Mulhall, C. Nelson, K. Paich, C. Saigal, T. Skolarus, J. Stanford, T. Walsh, C. E. Pollack

Abstract

Over half of men who receive treatment for prostate suffer from a range of sexual problems that affect negatively their sexual health, sexual intimacy with their partners and their quality of life. In clinical practice, however, care for the sexual side effects of treatment is often suboptimal or unavailable. The goal of the current study is to test a web-based intervention to support the recovery of sexual intimacy of prostate cancer survivors and their partners after treatment. The study team developed an interactive, web-based intervention, tailored to type of treatment received, relationship status (partnered/non-partnered) and sexual orientation. It consists of 10 modules, six follow the trajectory of the illness and four are theme based. They address sexual side effects, rehabilitation, psychological impacts and coaching for self-efficacy. Each includes a video to engage participants, psychoeducation and activities completed by participants on the web. Tailored strategies for identified concerns are sent by email after each module. Six of these modules will be tested in a randomized controlled trial and compared to usual care. Men with localized prostate cancer with partners will be recruited from five academic medical centers. These couples (N = 140) will be assessed prior to treatment, then 3 months and 6 months after treatment. The primary outcome will be the survivors' and partners' Global Satisfaction with Sex Life, assessed by a Patient Reported Outcome Measure Information Systems (PROMIS) measure. Secondary outcomes will include interest in sex, sexual activity, use of sexual aids, dyadic coping, knowledge about sexual recovery, grief about the loss of sexual function, and quality of life. The impact of the intervention on the couple will be assessed using the Actor-Partner Interaction Model, a mixed-effects linear regression model able to estimate both the association of partner characteristics with partner and patient outcomes and the association of patient characteristics with both outcomes. The web-based tool represents a novel approach to addressing the sexual health needs of prostate cancer survivors and their partners that-if found efficacious-will improve access to much needed specialty care in prostate cancer survivorship. Clinicaltrials.gov registration # NCT02702453 , registered on March 3, 2016.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 268 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 268 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 36 13%
Student > Master 35 13%
Student > Bachelor 26 10%
Student > Doctoral Student 22 8%
Researcher 17 6%
Other 42 16%
Unknown 90 34%
Readers by discipline Count As %
Nursing and Health Professions 48 18%
Psychology 40 15%
Medicine and Dentistry 35 13%
Social Sciences 7 3%
Computer Science 6 2%
Other 29 11%
Unknown 103 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2018.
All research outputs
#3,079,295
of 24,378,020 outputs
Outputs from BMC Cancer
#657
of 8,657 outputs
Outputs of similar age
#56,683
of 326,898 outputs
Outputs of similar age from BMC Cancer
#12
of 124 outputs
Altmetric has tracked 24,378,020 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,657 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,898 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 124 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.